Brief: CytomX Announces Milestone Achievement In Probody TCB Collab With Astellas
26/01/2023 12:11
Jan 26 (Reuters) - CytomX Therapeutics Inc CTMX.O :
* CYTOMX THERAPEUTICS ANNOUNCES MILESTONE ACHIEVEMENT IN
PROBODY® T-CELL ENGAGING BISPECIFIC (TCB) COLLABORATION WITH
ASTELLAS
* CYTOMX THERAPEUTICS INC - ACHIEVEMENT OF CLINICAL
CANDIDATE IS
FIRST IN MULTI-TARGET COLLABORATION AND TRIGGERS A $5 MILLION
MILESTONE PAYMENT TO CYTOMX
Source text for Eikon: ID:nGNX4G2tTl
Further company coverage: CTMX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CytomX Therapeutics
See all newsCytomX Q2 revenue misses, partly hurt by lower research activities in the Astellas collaboration
CytomX Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Cytomx Therapeutics Announces Appointment Of Charles Fuchs, M.D., M.P.H., To The Board Of Directors
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway